11β-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy

Min Huang1, Juan Liu1, Yunlu Sheng1

  • 1Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.

Insights

High-fat diets cause cardiac hypertrophy by increasing 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Inhibiting 11β-HSD1 can prevent this cardiac remodeling and dysfunction.

Area of Science:

  • Cardiovascular biology
  • Endocrinology
  • Molecular medicine

Background:

  • High-fat diet (HFD) is known to induce cardiac hypertrophy.
  • The precise cellular and molecular mechanisms driving HFD-induced cardiac dysfunction remain unclear.
  • 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which amplifies local glucocorticoid activity, was investigated for its role.

Purpose of the Study:

  • To investigate the role of 11β-HSD1 in the pathogenesis of cardiac dysfunction induced by a high-fat diet.
  • To explore the potential of targeting 11β-HSD1 as a therapeutic strategy for HFD-induced cardiac hypertrophy.

Main Methods:

  • Male Wistar rats were fed either a normal chow diet (NC) or HFD.
  • Cardiac remodeling and function were assessed using echocardiography and histology.
  • Primary neonatal rat ventricular cardiomyocytes (NRCMs) were treated with palmitic acid (PA) or lentivirus to study 11β-HSD1's role in hypertrophy.
  • Genome microarray analysis was performed on NRCMs to elucidate underlying mechanisms.

Main Results:

  • Palmitic acid induced NRCM hypertrophy, upregulating 11β-HSD1 expression and leading to increased cell size and cardiac hypertrophy gene expression.
  • Inhibition of 11β-HSD1 (using BVT.2733) or deficiency of 11β-HSD1 significantly reduced cardiomyocyte size.
  • Glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) antagonists (RU486 and spironolactone) attenuated 11β-HSD1-induced cardiomyocyte hypertrophy.
  • Genome microarray identified cAMP and calcium signaling pathways as downstream effectors of 11β-HSD1 in cardiomyocyte hypertrophy.
  • In HFD-fed rats, BVT.2733 treatment attenuated cardiac hypertrophy and improved cardiac function.

Conclusions:

  • 11β-HSD1 plays a crucial role in regulating cardiac remodeling through both GR and MR pathways.
  • Pharmacological inhibition of 11β-HSD1 presents a potential therapeutic approach for preventing high-fat diet-induced cardiac hypertrophy.
Abstract

Related Concept Videos

Transcription Attenuation in Prokaryotes02:42

Transcription Attenuation in Prokaryotes

Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure.  Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442